Academic History
Charlotte Pawlyn, BA, MBBChir, MRCP, PhD, FRCPath, is a Hematologist and CRUK Clinician Scientist at The Institute of Cancer Research, London, UK. She is also the Group Leader of the Myeloma Biology and Therapeutics Group in the Division of Cancer Therapeutics.
Dr Pawlyn obtained degrees in Pharmacology and Medicine from St John’s College, University of Cambridge, Cambridge, UK. She completed her initial medical training in the East Anglian and North London deaneries and Hematology specialty training at the Royal Marsden Hospital and in the South West London Deanery. She also has a PhD Fellowship at The Institute of Cancer Research, focused on novel epigenetic targets for myeloma therapy.
Dr Pawlyn received the Women in Cancer Research Scholar Award from the American Association of Cancer Research. She is also involved in several clinical trials through the UK NCRI group and the UK Myeloma Research Alliance (UKMRA), and serves on the Research Advisory Group for Myeloma UK.
Speaking on the Myeloma XI clinical trial and resistance mechanisms in multiple myeloma
Dr Pawlyn has a special research interest in therapeutic targets for improving outcomes in patients with immunomodulatory drug-resistant and high-risk myeloma. She discusses the Myeloma XI trial (NCT01554852), which investigated lenalidomide maintenance for newly diagnosed myeloma, and resistance mechanisms to targeted therapies in myeloma.
